| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 06/01/2006 | WO2004091550A3 Compositions and methods for delivering thymosin beta 4, analogues, isoforms and other derivatives |
| 06/01/2006 | US20060116510 Isoflavone concentrates, as well as methods for their production |
| 06/01/2006 | US20060116508 Novel 27411, 23413, 22438, 23553, 25278, 26212, NARC SC1, NARC 10A, NARC 1, NARC 12, NARC 13, NARC17, NARC 25, NARC 3, NARC 4, NARC 7, NARC 8, NARC 11, NARC 14A, NARC 15, NARC 16, NARC 19, NARC 20, NARC 26, NARC 27, NARC 28, NARC 30, NARC 5, NARC 6, NARC 9, NARC 10C, NARC 8B, NARC 9, NARC2A, NARC 16B, NARC 1C, NARC 1A, NARC 25, 86604 and 32222 molecules and uses therefor |
| 06/01/2006 | US20060116428 Intravitreally-injectable solution for the treatment of vitreous hemorrhages |
| 06/01/2006 | US20060116422 Prodrugs built as multiple self-elimination-release spacers |
| 06/01/2006 | US20060116356 Phosphonate analogs of HIV integrase inhibitor compounds |
| 06/01/2006 | US20060116348 Using the hyaluronate synthase from Pasteurella multocida; coatings for biomaterials wherein the coatings provide protective properties to the biomaterial and/or act as a bioadhesive; coatings could be applied to electrical devices, sensors, catheters |
| 06/01/2006 | US20060116346 Taxanes covalently bounded to hyaluronic acid or hyaluronic acid derivatives |
| 06/01/2006 | US20060116337 Use of glycyrrhizin and its derivatives as MCP-1 production inhibitors |
| 06/01/2006 | US20060115874 Enrichment method for variant proteins with altered binding properties |
| 06/01/2006 | US20060115542 Therapeutic delivery of carbon monoxide |
| 06/01/2006 | US20060115533 Pharmaceutical compositions |
| 06/01/2006 | US20060115528 Rapidly disintegrating tablet |
| 06/01/2006 | US20060115518 Liquid seasoning |
| 06/01/2006 | US20060115517 Liquid seasoning |
| 06/01/2006 | US20060115500 Ophthalmic ointment composition comprising a drug, an ointment base and a solubilizing/dispersing agent |
| 06/01/2006 | US20060115478 Compositions and methods for treating and preventing type-1 diabetes |
| 06/01/2006 | US20060115451 Modified cytokines for use in cancer therapy |
| 06/01/2006 | US20060115449 Bioabsorbable, biobeneficial, tyrosine-based polymers for use in drug eluting stent coatings |
| 06/01/2006 | US20060115376 Irradiation in presence of stabilizer; preventing degradation |
| 06/01/2006 | DE19910102B4 Proteinkonjugate, Verfahren, Vektoren, Proteine und DNA zu deren Herstellung, deren Verwendung, sowie Arzneimittel und Impfstoffe mit einem Gehalt derselben Protein conjugates, methods, vectors, proteins, and DNA for their preparation, their use, as well as drugs and vaccines containing the same |
| 06/01/2006 | DE19901687B4 Opioide Analgetika mit kontrollierter Wirkstofffreisetzung Opioid analgesics controlled release |
| 06/01/2006 | DE102004058893A1 New modified biopolymer (obtained by reacting a bio polymer with glucuronic acid) useful e.g. for the induction or promotion of the biomineralization and the production of biomaterial; and as bone replacement material |
| 06/01/2006 | DE102004057196A1 Verfahren zur Herstellung von Albumin-Konjugaten mit Nicht-steroidalen Antirheumatika (NSAR) Process for the preparation of albumin conjugates with non-steroidal anti-inflammatory drugs (NSAIDs) |
| 06/01/2006 | DE10016881B4 Gezielte Transfektion von Zellen mittels biotinyliertem Dendrimer Targeted transfection of cells using biotinylated dendrimer |
| 06/01/2006 | CA2589455A1 Process for producing albumin conjugates with non-steroidal antirheumatic agents (nsar) |
| 06/01/2006 | CA2589242A1 Solid formulations of liquid biologically active agents |
| 06/01/2006 | CA2589218A1 Stable crystal modifications of dotap chloride |
| 06/01/2006 | CA2589200A1 Formulations of pyridoxal -5'-phosphate and methods of preparation |
| 06/01/2006 | CA2589169A1 Solid, oral, microparticulate dosage form which has been designed to prevent misuse |
| 06/01/2006 | CA2589160A1 Solid, oral drug form which has been designed to prevent misuse |
| 06/01/2006 | CA2588338A1 Compositions comprising azelastine and methods of use thereof |
| 06/01/2006 | CA2584427A1 Triple natural polymer viscoelastic composition |
| 06/01/2006 | CA2527750A1 A dried product and a process for manufacturing the product |
| 05/31/2006 | EP1661584A1 Use of conjugates of amatoxins and phallotoxins with macromolecules for cancer and inflammation therapy |
| 05/31/2006 | EP1661573A1 Ophthalmic composition |
| 05/31/2006 | EP1661570A2 Compositions comprising ipatropium and xylometazoline for treatment of the common cold |
| 05/31/2006 | EP1661557A1 Materials and methods for making improved micelle compositions |
| 05/31/2006 | EP1661556A1 Medicinal preparation having improved dissolution properties |
| 05/31/2006 | EP1660859A2 T1r hetero-oligomeric taste receptors, cell lines that express said receptors, and taste compounds |
| 05/31/2006 | EP1660638A2 Lipoparticles comprising proteins, methods of making, and using the same |
| 05/31/2006 | EP1660630A2 Nucleic acid biomaterials and methods of formation and use |
| 05/31/2006 | EP1660596A1 Microorganism coating components, coatings, and coated surfaces |
| 05/31/2006 | EP1660522A2 Pharmaceutical composition with increased bioavailability suitable for the administration of oral retroviral protease inhibitors. process for preparing a concentrate pharmaceutical composition comprising a retroviral protease inhibitor |
| 05/31/2006 | EP1660519A2 Fluorinated carbohydrate conjugates |
| 05/31/2006 | EP1660513A2 A ca6 antigen-specific cytotoxic conjugate and methods of using the same |
| 05/31/2006 | EP1660153A2 Hydrogel nanocompsites for ophthalmic applications |
| 05/31/2006 | EP1660145A2 Active agent delivery systems, including a single layer of a miscible polymer blend, medical devices and methods |
| 05/31/2006 | EP1660134A2 Conjugates of hydroxyalkyl starch and g-csf |
| 05/31/2006 | EP1660133A1 Targeted delivery of anti-viral compounds through hemoglobin bioconjugation |
| 05/31/2006 | EP1660101A1 Liquid formulations for the prevention and treatment of mucosal diseases and disorders |
| 05/31/2006 | EP1660099A1 Intravascular delivery of non-viral nucleic acid |
| 05/31/2006 | EP1660083A2 Stable pharmaceutical composition of rabeprazole |
| 05/31/2006 | EP1660054A1 Agent containing ergolin for transdermal application |
| 05/31/2006 | EP1660053A2 Skeletally targeted nanoparticles |
| 05/31/2006 | EP1660047A1 Micro-particle fatty acid salt solid dosage formulations for therapeutic agents |
| 05/31/2006 | EP1660039A2 Prevention of molecular weight reduction of the polymer, impurity formation and gelling in polymer compositions |
| 05/31/2006 | EP1660038A1 Steroidal compositions containing hydroxycarboxylic acids and methods of using the same |
| 05/31/2006 | EP1660037A2 Methods for administering aripiprazole |
| 05/31/2006 | EP1660029A2 Compositions containing topical active agents and pentylene glycol |
| 05/31/2006 | EP1659881A2 Novel flavors, flavor modifiers, tastants, taste enhancers, umami or sweet tastants, and/or enhancers and use thereof |
| 05/31/2006 | EP1467737B1 Orally dispersible pharmaceutical piribedil composition |
| 05/31/2006 | EP1416918B1 Synergistic filler composition |
| 05/31/2006 | EP1352061B1 Method for inhibiting the expression of a target gene |
| 05/31/2006 | EP1338288B1 Cellulosic particles for pharmaceutical preparations |
| 05/31/2006 | EP1315500A4 Pharmaceutical compositions for topical delivery of cyclooxygenase-2 enzyme inhibitors |
| 05/31/2006 | EP1272223B1 Therapeutic and diagnostic ligand systems comprising transport molecule binding properties and medicaments containing the same |
| 05/31/2006 | EP1263467B1 Paste formulations comprising silica |
| 05/31/2006 | EP1242012A4 Improved transdermal contraceptive delivery system and process |
| 05/31/2006 | EP1221957B1 Method for preparing a composition by mother-of-pearl extraction,and use thereof in cosmetics and dermatology |
| 05/31/2006 | EP1212084B1 Method of separating rotavirus variants and live attenuated rotavirus vaccine |
| 05/31/2006 | EP1207910B1 Composition comprising diagnostic agents in silica-coated containers |
| 05/31/2006 | EP1202719B1 Anesthetic composition for intravenous injection comprising propofol |
| 05/31/2006 | EP1198580B1 Scleroprotein of an adeno-associated virus with modified chromatographic properties, the production thereof and use of the same |
| 05/31/2006 | EP1175489B1 Oligonucleotides containing an antisense sequence stabilised by a secondary structure and pharmaceutical compositions containing same |
| 05/31/2006 | EP1121109B1 Biphasic tramadol preparation |
| 05/31/2006 | EP1067908B1 Taxane microemulsions |
| 05/31/2006 | EP1067898B1 Artificial nail compositions and related methods |
| 05/31/2006 | EP1030651A4 Novel oral dosage form for carvedilol |
| 05/31/2006 | CN1780865A Amphiphilic block copolymer and polymeric composition comprising the same for drug delivery |
| 05/31/2006 | CN1780851A Method and carrier complexes for delivering molecules to cells |
| 05/31/2006 | CN1780824A Compositions and methods for preventing and treating endotoxin-related diseases and conditions. |
| 05/31/2006 | CN1780643A Antiviral phosphonate analogs |
| 05/31/2006 | CN1780641A Single chain antigen-binding polypeptides for polymer conjugation |
| 05/31/2006 | CN1780610A Pharmaceutical composition in the form of a hydrogel for transdermal administration of active substances |
| 05/31/2006 | CN1780607A Zinc-containing sustained-release composition, its preparation, and method for producing the same |
| 05/31/2006 | CN1780596A Random and non-random alkylene oxide polymer alloy compositions |
| 05/31/2006 | CN1780555A Nasal administration of the LH-RH analog leuprolide |
| 05/31/2006 | CN1778392A Excipient of oral medicine |
| 05/31/2006 | CN1257975C Plasmid of recombinant immunotoxin Rantes-DT390 aimed at activating Th1 cell, and its preparing method and use |
| 05/31/2006 | CN1257708C Modified water-soluble medicine and vaccine embedded macromolecule microsphere preparation method |
| 05/30/2006 | US7053243 3-Methoxybenzyl thiourea derivatives and improved lipid compositions containing same |
| 05/30/2006 | US7053209 sustained release; may be diluted with solvent for administration |
| 05/30/2006 | US7053187 Sperm-specific monoclonal antibody, mAbC |
| 05/30/2006 | US7053150 Segmented polymers and their conjugates |
| 05/30/2006 | US7053146 Compositions containing copolymers based on acryloyldimethyl aminoethylsulfonic acid and synergistic additives |
| 05/30/2006 | US7053125 Controlled dispersion of colloidal suspension by comb polymers |
| 05/30/2006 | US7053069 Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives |
| 05/30/2006 | US7053068 Chitosan-thio-amidine conjugates and their cosmetic as well as pharmaceutic use |
| 05/30/2006 | US7053061 Vegetable oil phase containing dispersed Amphotercin B; water phase containing dissolved glycerin, mannitol, or dextrose tonicity modifiers; emulsifier such as natural phosphatides |